Three consecutive earnings beats — including a 23% positive surprise in the most recent quarter — and solid technical momentum have carried the stock above its near-term take-profit resistance level, leaving the reward-to-risk ratio negative and the setup more consistent with a hold than a new entry; a flagged dividend sustainability concern adds a tail risk for income-oriented investors.
Thesis pillars
- Price Above Take Profit Ceiling→Stable
- Solid Momentum Flattening Slope↓Deteriorating
- Dividend Sustainability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 20, 2026
Kenvue Inc. (KVUE) Stock Analysis
Consumer Defensive · Household & Personal Products
Wait for pullback to $18.91. Price sits above the model's entry target of $18.91; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away).
Kenvue manufactures and markets consumer health products across three segments — Self Care (Tylenol, Zyrtec), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (BAND-AID, Listerine, Johnson's) — sold in more than 165 countries. The company generated $15.1 billion... Read more
Wait for pullback to $18.91. Price sits above the model's entry target of $18.91; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Score 5.3/10, moderate confidence.
Passes 5/9 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: moderate.
About Kenvue Inc.
About Kenvue Inc.
Kenvue generated $15.1 billion in Net sales in FY2025, marketing consumer health products in more than 165 countries through three segments: Self Care (Tylenol, Zyrtec, Nicorette), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (BAND-AID, Listerine, Johnson's). The company employed approximately 22,000 people at December 28, 2025, distributed across APAC (30%), EMEA (28%), North America (23%), and LATAM (19%). In-house facilities delivered roughly 60% of sales volume in FY2025.
Kenvue earns revenue selling over-the-counter medicines and personal care products at retail and through digital channels. The Self Care segment competes with Haleon, Procter & Gamble, and Reckitt Benckiser Group; Skin Health and Beauty competes with Beiersdorf, Estée Lauder, L'Oréal, Procter & Gamble, and Unilever; Essential Health competes with Church & Dwight and Colgate-Palmolive. Product development is supported by approximately 1,600 scientists, doctors, pharmacists, and engineers operating through a network of global innovation hubs. Principal raw materials — resins, vegetable oils, pulp, and oleochemicals — are purchased primarily from third-party suppliers; no single supplier provides a significant portion of total material requirements, though certain raw and packaging materials are sourced from single-source or limited suppliers. The company's digital marketing approach incorporates influencer and celebrity partnerships alongside precision targeting.
Show full overview
A pending acquisition by Kimberly-Clark, announced November 2, 2025 and approved by Kenvue shareholders on January 29, 2026, would convert each Kenvue share into 0.14625 K-C shares plus $3.50 cash. The exchange ratio is fixed and does not adjust for K-C stock price fluctuations before closing, exposing Kenvue shareholders to K-C market risk during the interim period. The 10-K notes foreign regulatory approvals remain outstanding as of the filing date, and that failure to consummate the transaction could adversely affect Kenvue's business, financial condition, and stock price.
See also: Consumer Defensive · Household & Personal Products
From Kenvue Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Kenvue Inc.
Latest news
- NEWS Kenvue Inc. (NYSE:KVUE) to Issue Quarterly Dividend of $0.21 - MarketBeat — MarketBeat positive
- NEWS Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook - TradingView — TradingView positive
- NEWS What Are Wall Street Analysts' Target Price for Kenvue Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS What Did Kenvue (NYSE:KVUE) Show in Its Latest Quarter? - Kalkine Media — Kalkine Media neutral
- NEWS Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes - PR Newswire — PR Newswire neutral
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-15Item 5.02MEDIUMCFO Amit Banati to step down effective May 12, 2026; announced February 12, 2026. Chief Accounting Officer Heather Howlett appointed interim CFO effective May 12, 2026. No permanent replacement named. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $18.91. Price sits above the model's entry target of $18.91; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 1 day. Wait until post-earnings. Analyst target $16.96 reached (−12.2%), stop $18.15 (−6.5%), A.R:R -1.1:1. Score 5.3/10, moderate confidence.
Analyst target $16.96 reached (−12.2% from $19.33); no take-profit level is published. Analyst target $16.96 reached (−12.2%), stop $18.15 (−6.5%), A.R:R -1.1:1. Stop-loss: $18.15.
Analyst target reached - limited upside remaining; Near 52-week high (4.0% away); Weak growth.
Kenvue Inc. trades at a P/E of 22.5 (forward 15.6). TrendMatrix value score: 5.7/10. Verdict: Buy (Wait for Entry).
20 analysts cover KVUE with a consensus score of 3.4/5. Average price target: $20.
What does Kenvue Inc. do?Kenvue manufactures and markets consumer health products across three segments — Self Care (Tylenol, Zyrtec), Skin...
Kenvue manufactures and markets consumer health products across three segments — Self Care (Tylenol, Zyrtec), Skin Health and Beauty (Neutrogena, Aveeno), and Essential Health (BAND-AID, Listerine, Johnson's) — sold in more than 165 countries. The company generated $15.1 billion in Net sales in FY2025 with approximately 22,000 employees.